Clinical Trials Browser

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

NCT02495103 2021-01-26

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

Phase 1/2 Terminated

7 enrolled 10 charts

Genitourinary

Carcinoma, Renal Cell

NCT00459121 2019-03-26

Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery

Phase 2 Terminated

2 enrolled 4 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00923247 2018-11-29

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Phase 1/2 Terminated

22 enrolled 21 charts

Head & Neck

Neoplasms, Thyroid Neoplasms, Carcinoma, Medullary

NCT00481845 2017-02-07

Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer

Phase 2 Terminated

1 enrolled 8 charts

Breast

Breast Neoplasms

NCT00686036 2016-12-21

ZENITH

Phase 2 Terminated

17 enrolled 4 charts

Genitourinary

Prostatic Neoplasms

NCT00752986 2016-12-05

ZACFAST

Phase 2 Terminated

39 enrolled 7 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00597116 2016-10-10

An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

Phase 2 Terminated

25 enrolled 8 charts

Other solid neoplasmThoracic

Mesothelioma, Recurrence

NCT00862836 2016-10-10

ZACFAST

Phase 1/2 Terminated

15 enrolled 13 charts

Gynecologic

Ovarian Neoplasms

NCT00290537 2016-05-19

Phase II Study of ZD6474 in Advanced NSCLC

Phase 2 Terminated

4 enrolled 3 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00720083 2015-11-17

Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer

Phase 2 Terminated

34 enrolled 5 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01372813 2015-10-23

Vandetanib to Treat Advanced Kidney Cancer

Phase 2 Terminated

3 enrolled 10 charts

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

NCT00445549 2012-06-26

Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Terminated

12 enrolled 5 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Clinical Trials

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer

ZENITH

ZACFAST

An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

ZACFAST

Phase II Study of ZD6474 in Advanced NSCLC

Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer

Vandetanib to Treat Advanced Kidney Cancer

Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer